STOCK ALARMPRO
Continuous market monitoring. Instant alerts.
Free Account

SOLV

NYSEMarket Closed

Solventum Corporation

$82.95
+$0.16 (+0.20%)
As of 4:31 AM
Open
$83.11
High
$83.55
Low
$82.18
Prev Close
$82.79
52W High
$88.20
52W Low
$60.70
Volume
536.61K
Mkt Cap
$14.39B
OverviewChartNews

Latest News

Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
prnewswire.com

Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care Solventum™  Prevena™ Therapy is the only closed incision negative pressure therapy system with fully integrated linear and area dressings solely indicated for closed incisions that utilize ROCF technology ST. PAUL, Minn.

Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not
seekingalpha.com

Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not

Solventum offers an interesting risk/reward profile, with improving margins, disciplined reinvestment, and potential revenue growth acceleration offsetting modest core revenue growth concerns. The $725M+ Acera Surgical acquisition provides entry into a double-digit growth wound care market, though it introduces operating and sentiment risks. SOLV's 'Transform for the Future' initiative targets $500M annual cost savings, aiming to boost operating margins above 23% by 2028.

Advisors Asset Management Inc. Lowers Stake in Solventum Corporation $SOLV
defenseworld.net

Advisors Asset Management Inc. Lowers Stake in Solventum Corporation $SOLV

Advisors Asset Management Inc. cut its holdings in Solventum Corporation (NYSE: SOLV) by 72.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,290 shares of the company's stock after selling 16,351 shares during the quarter. Advisors Asset Management Inc.'s holdings

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Albemarle, Circle Internet, Cloudflare, Danaher, Inspire Medical, Six Flags, Workday and More
247wallst.com

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Albemarle, Circle Internet, Cloudflare, Danaher, Inspire Medical, Six Flags, Workday and More

Pre-Market Stock Futures: The futures are trading higher this morning. Sellers regained the upper hand on Monday, starting the final trading month of 2025 on the downside after a blazing Thanksgiving-week rally. All of the major indices finished the day lower, and once again, cryptocurrencies were hammered. Numerous reasons for the selling on Monday, not... Here Are Tuesday's Top Wall Street Analyst Research Calls: Albemarle, Circle Internet, Cloudflare, Danaher, Inspire Medical, Six Flags, Workday and More.

Solventum Corporation $SOLV Shares Sold by Creative Planning
defenseworld.net

Solventum Corporation $SOLV Shares Sold by Creative Planning

Creative Planning reduced its position in shares of Solventum Corporation (NYSE: SOLV) by 5.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,970 shares of the company's stock after selling 1,534 shares during the period. Creative Planning's holdings

Solventum Corporation $SOLV Stock Position Raised by Boston Partners
defenseworld.net

Solventum Corporation $SOLV Stock Position Raised by Boston Partners

Boston Partners increased its holdings in shares of Solventum Corporation (NYSE: SOLV) by 9.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,670,757 shares of the company's stock after acquiring an additional 308,784 shares during the quarter. Boston Partners

Solventum Announces Agreement to Acquire Acera Surgical
prnewswire.com

Solventum Announces Agreement to Acquire Acera Surgical

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space, a part of the broader regenerative tissue matrices category within acute care settings, a $900 million market segment in the U.S. Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency ST. PAUL, Minn.

Solventum Corporation (SOLV) Presents at Stifel 2025 Healthcare Conference Transcript
seekingalpha.com

Solventum Corporation (SOLV) Presents at Stifel 2025 Healthcare Conference Transcript

Solventum Corporation ( SOLV ) Stifel 2025 Healthcare Conference November 12, 2025 11:20 AM EST Company Participants Wayde McMillan - Chief Financial Officer Doug Bartlett Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Frederick Wise Stifel, Nicolaus & Company, Incorporated, Research Division Luckily, Wayde is not the Chief Executive Officer. He tells me, I'm not sure.

Solventum: A Mixed Q3 Provides Further Support For Our Neutral Stance
seekingalpha.com

Solventum: A Mixed Q3 Provides Further Support For Our Neutral Stance

Solventum which has barely moved since our coverage 14 months back, delivered mixed Q3 results last week. SOLV managed to beat both topline and bottomline estimates (although the degree of beat on the latter wasn't as strong as previous quarters), but revenue trends continue to slow. Margin pressures persist due to tariffs (the impact of which will be worse next year), but SOLV's new multi-year restructuring program and its ongoing efforts on programmatic savings may provetobehandy.